Madison Clarke
The P.1 'Brazilian' strain of COVID-19 may be less resistant to vaccine-induced antibodies than initially feared, according to a study by the University of Oxford. The research, which has not yet been peer-reviewed, found that the Pfizer-BioNTech COVID-19 vaccine was able to efficiently neutralise the Brazil variant. However, the study also showed a nearly three-fold reduction in the level of virus neutralisation by the antibodies generated by the vaccines for the P1 Brazil variant when compared to the original 'Victoria' strain. The Oxford/AstraZeneca vaccine has been found to be less effective against the variant first identified in South Africa, leading to a pause in its rollout in South Africa.
Explore related products
What You'll Learn
- The Pfizer-BioNTech vaccine can neutralise the Brazilian variant
- The Oxford/AstraZeneca vaccine is less effective against the Brazilian variant
- The Brazilian variant is more resistant to antibodies
- The Brazilian variant has 11 mutations in the spike protein region
- Vaccines will likely still provide some protection against the Brazilian variant
The Pfizer-BioNTech vaccine can neutralise the Brazilian variant
The study was conducted by scientists from Pfizer and BioNTech, in collaboration with the University of Texas Medical Branch. Blood serum samples were taken from people who had received both doses of the Pfizer-BioNTech vaccine and were tested against an engineered version of the virus containing the same mutations as the Brazilian variant. The results showed that the vaccine-induced antibodies were able to neutralise the variant, suggesting that the vaccine can provide protection against it.
While the research offers optimism, it is important to note that the Brazilian variant may still be less resistant to vaccine-induced antibodies than initially feared. The South African variant, for instance, has proven to be more challenging to target. However, the Pfizer-BioNTech vaccine has also shown "robust but lower" activity against this strain.
The Oxford University study, which has not yet been peer-reviewed, found a nearly three-fold reduction in the level of virus neutralisation by the antibodies generated by the Oxford and Pfizer vaccines for the Kent and Brazil variants when compared to the original strain. This suggests that while the vaccines may be effective against the Brazilian variant, they may not work as well as against the original strain of the virus.
Overall, the Pfizer-BioNTech vaccine's ability to neutralise the Brazilian variant is promising, but it is important to continue following COVID-19 health precautions, such as wearing masks and social distancing, even after being fully vaccinated.
Rabies Vaccination: Adult Immunization Requirements and Recommendations
You may want to see also
Explore related products
The Oxford/AstraZeneca vaccine is less effective against the Brazilian variant
The Oxford/AstraZeneca vaccine may be less effective against the Brazilian variant of the coronavirus, according to some early studies. The Brazilian variant, known as P.1, shares similarities with the South African variant, which has shown reduced efficacy against the Oxford/AstraZeneca vaccine.
A preliminary study by Oxford University found that the P.1 variant resulted in a three-fold reduction in neutralization power for the AstraZeneca vaccine when compared to the original Victoria strain. This is a significant decrease in protection, but it is important to note that vaccine-induced antibodies can still neutralize the variant, albeit at lower levels.
The South African variant, by comparison, resulted in an even greater reduction in vaccine efficacy, with a 7.6-fold reduction in neutralization power for the Pfizer vaccine and a 9-fold reduction for the AstraZeneca vaccine. This led to South Africa pausing the use of the AstraZeneca vaccine as it provided minimal protection against mild-to-moderate infections caused by the country's dominant variant.
While the Brazilian variant may pose a similar threat, early findings from Oxford University suggest that the P.1 variant is less resistant to vaccine-induced immune responses than the South African variant. This indicates that the Oxford/AstraZeneca vaccine may still provide some level of protection against the Brazilian variant, despite the reduced efficacy.
It is important to note that vaccine development is an ongoing process, and researchers are continuously working to improve the effectiveness of vaccines against new variants. The understanding of the Brazilian variant and its impact on vaccine efficacy is still evolving, and further studies are needed to confirm these early findings.
The Vaccine: Is it in Our Food?
You may want to see also
Explore related products
The Brazilian variant is more resistant to antibodies
The Brazilian variant, known as P.1, is a highly contagious mutation of the COVID-19 virus. It was first detected in the city of Manaus, Brazil, and has since spread rapidly across the country. This variant is of particular concern because it is able to evade 25-61% of protective immunity elicited by previous infection.
Danny Altmann, a professor of immunology at Imperial College, stated that it is “likely” the Brazilian variant is “breaking through" antibodies built up by previous infection. This is supported by the fact that a large number of people in Manaus who had recovered from COVID-19 and developed antibodies still contracted the P.1 variant during a resurgence in January.
While the Brazilian variant does show some resistance to antibodies, existing COVID-19 vaccines may still offer protection. A study by Oxford University found that natural and vaccine-induced antibodies could neutralize the P.1 variant, but at lower levels. This suggests that the Brazilian strain may be less resistant to antibodies than initially feared.
Furthermore, a study published in the New England Journal of Medicine found that the Pfizer-BioNTech COVID-19 vaccine was able to "efficiently" neutralize the Brazilian variant. This provides hope that vaccines can protect against the P.1 variant, even if it has some degree of resistance to antibodies.
It is important to note that the goal of COVID-19 vaccines is to prevent severe disease, hospitalization, and death. Even if a person contracts the virus after being vaccinated, the vaccine can still provide protection against the worst outcomes. As new variants emerge, it is crucial to continue monitoring the effectiveness of vaccines and updating them as necessary to ensure ongoing protection against COVID-19 and its variants.
Vaccination Requirements for Broadway Shows: What You Need to Know
You may want to see also
Explore related products
The Brazilian variant has 11 mutations in the spike protein region
The SARS-CoV-2 virus, which causes COVID-19, is known to accumulate mutations in its genetic sequence over time. These mutations can lead to new variants with distinct characteristics, and the emergence of new variants is an expected and ongoing occurrence. The P.1 variant, commonly known as the Brazilian variant, is one such variant that arose independently in Brazil and fuelled secondary outbreaks in the country.
The Brazilian variant, or P.1 variant, has been associated with increased transmissibility, immune evasion, and mortality. It has 11 mutations in the spike protein region, including L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, H655Y, and T1027I. These mutations are of particular concern because the spike protein is the primary target for COVID-19 vaccine development. Changes in the spike protein structure may disrupt original vaccine development plans and pose challenges in creating effective vaccines.
However, studies suggest that existing vaccines may still provide some protection against the Brazilian variant. Research from the University of Oxford indicates that vaccine-induced antibodies can neutralise the P.1 variant, although at lower levels compared to the original strain. The Pfizer-BioNtech COVID-19 vaccine, in particular, has been found to ""efficiently" neutralise the Brazilian variant in a study published in the New England Journal of Medicine.
While fully vaccinated individuals may have some protection against the Brazilian variant, it is still important to follow COVID-19 health precautions, such as wearing masks, social distancing, and maintaining good hygiene practices, especially when interacting with unvaccinated or high-risk individuals. Additionally, ongoing genomic surveillance and characterisation of emerging variants are crucial to understanding their impact on vaccine efficacy, transmission, and severity.
Coronavirus Vaccines: What We Know So Far
You may want to see also
Explore related products
Vaccines will likely still provide some protection against the Brazilian variant
The Brazilian variant, also known as the P.1 variant, is a highly transmissible mutation of the Covid-19 virus. It was first detected in Brazil and has since spread to other parts of the world. This variant has raised concerns due to its large number of mutations, particularly in the spike protein region, which is a critical target for the immune system's protective response.
While the full extent of the Brazilian variant's impact is still uncertain, studies suggest that existing vaccines may provide some protection against it. A University of Oxford study found that vaccine-induced antibodies can neutralise the P.1 variant, although at lower levels than the original strain. This reduction in neutralisation capacity was also observed in other variants, such as the B.1.1.7 (UK) and B.1.351 (South Africa) variants. However, the P.1 variant may be less resistant to antibodies than initially feared, offering some reassurance.
The Pfizer-BioNTech COVID-19 vaccine has been specifically tested against the P.1 variant, and it was found to efficiently neutralise the virus. This provides strong evidence that this vaccine can protect against the Brazilian variant. Additionally, Professor Christine Carrington from the University of the West Indies has stated that the AstraZeneca vaccine can also provide sufficient protection against the P.1 variant, despite its reduced efficacy.
It is important to remember that even in cases of reduced vaccine efficacy against specific variants, vaccinations still offer significant protection against severe disease, hospitalisation, and death. Therefore, getting vaccinated remains crucial, even in the presence of variants like the P.1 Brazilian strain. Vaccines continue to be our best defence against COVID-19 and its variants, and they help prepare our immune systems to respond effectively to the challenges posed by these evolving viruses.
California's Vaccination Rules for the Allergy-Prone
You may want to see also
Frequently asked questions
Studies suggest that the Pfizer-BioNTech COVID-19 vaccine can protect against the Brazil variant.
The Brazil variant, also known as the P.1. strain, was first identified in Brazil in 2020.
The Pfizer-BioNTech vaccine was found to efficiently neutralise the Brazil variant in a study. However, it is important to note that fully vaccinated people should still follow COVID health precautions, such as wearing masks and social distancing, to protect those who are unvaccinated or at high risk.
In addition to the Pfizer-BioNTech vaccine, studies from the University of Oxford suggest that existing COVID-19 vaccines, including the Oxford-AstraZeneca vaccine, may also provide some protection against the Brazil variant.
The effectiveness of the vaccines against the Brazil variant was determined by comparing the levels of virus neutralisation by antibodies generated by the vaccines. Blood samples from individuals with natural antibodies from COVID-19 infection and those who had received the vaccines were used in these studies.
